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Hemangiopericytomas are vascular tumors with a susceptibility to arise anywhere in the human body. We present a case of a 68year-old female with primary omental hemangiopericytoma and a two-time recurrence managed with surgery and close follow-up.
The first recurrence was at 52 months and the second at 37 months following the prior presentation. No adjuvant chemotherapy
or radiation therapy was administered. Given the widespread nature of the cell of origin, routine follow-up postoperatively
with interval imaging in order to detect recurrences is imperative. Pathologic tumor characteristics may determine potential for
recurrence and may also assist in determining whether adjuvant treatment modalities should be included in the management plan.
Review of the English literature reveals a total of 24 cases of omental hemangiopericytomas inclusive of the current report.

1. Introduction
Hemangiopericytomas are a rare form of vascular tumors
that arise from the pericytes of Zimmerman that surround
capillaries and function to regulate blood flow. They were first
recognized by Schmidt in 1937 and fully described and named
by Stout and Murray in 1942 [1]. Given the cell of origin, these
vascular tumors can arise anywhere in the body. The most
common sites reported are the lower limb musculature, pelvic
fossa, retroperitoneum, and the head and neck region [2, 3].
Median age of onset is variable ranging from 45 to 55 years
with an equal predilection for men and women [2, 3]. The
classic pathologic appearance of a hemangiopericytoma is a
well-encapsulated hypervascular tumor [4]. We present a case
of primary omental hemangiopericytoma with subsequent
local recurrences.

2. Case Report
A 68-year-old G1P1001 Caucasian female with a known past
medical history of hyperlipidemia, gastroesophageal reflux
disease, and depression presented in 2006 with complaints

of dull, achy pain located in the lower abdomen. She underwent endoscopic evaluation by her gastroenterologist with
negative findings. As part of the work-up, she had a pelvic
ultrasound, which demonstrated a large, solid heterogeneous
mass superior to the ovaries measuring 15.4 × 14.7 × 8.6 cm
with prominent internal blood flow. CA-125 (cancer antigen125) was elevated at 77 U/mL with normal CEA (carcinoembryonic antigen), AFP (alpha-fetoprotein), and 𝛽HCG
(beta-human chorionic gonadotropin). She underwent an
exploratory laparotomy with lysis of adhesions and resection
of the abdominal tumor with partial omentectomy because
of concern for a primary ovarian carcinoma. Intraoperative
findings included numerous dilated blood vessels in the
omentum measuring up to 1.5 cm in diameter with a 25 ×
20 cm soft, friable mass. The mass occupied most of the
midabdomen, encasing the omentum, and was attached to
the sigmoid mesentery and bladder peritoneum. The ovaries,
uterus, and remaining pelvic structures were normal in
appearance. There was no evidence of metastatic disease. The
estimated blood loss (EBL) at the time of surgery was 1 liter
and the patient received 2 units of packed red blood cells
(PRBCs). Final pathology revealed “hemangiopericytoma of
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Figure 1: (a) Microscopic description: the tumor is cellular and
composed of many variable ectatic and compressed thin walled
branching vessels, giving staghorn configuration. The surrounding
tumor cells are spindled to round with scant pale to eosinophilic
cytoplasm, bland vesicular nuclei, and low mitotic activity. (b)
Immunohistochemically, the tumor cells stain positive for CD34.
The combined morphology and immunoprofile are consistent with
hemangiopericytoma.

the abdomen with low malignant potential.” Histological
findings showed a staghorn vascular pattern with solid
perivascular areas formed by plump, comma-shaped cells
with rare mitoses (less than 2 per 10 high power fields (HPF))
(Figure 1(a)). On immunohistochemical examination, tumor
cells exhibited vimentin and CD34 positivity (a marker
for vascular endothelial cells) with CD31 highlighting the
vasculature (Figure 1(b)). S-100, keratin, and EMA were
all negative; reticulin staining was positive surrounding the
cords of cells. The patient did not receive any further adjuvant
treatment and continued to follow up with her gynecologist
oncologist.
She presented again to the gynecology oncology clinic in
early 2011, 52 months after her primary surgery with symptoms of a “pinching sensation” and concerns for a palpable

mass in the left lower quadrant of her abdomen of few
months’ duration. Computed tomography (CT) imaging of
the abdomen and pelvis revealed interval development of a 2
× 1 cm hyperdense soft tissue lesion with a midline pelvic ventral hernia. Follow-up magnetic resonance imaging (MRI)
showed a 2.1 × 1.5 cm ovoid-shaped mass probably originating
in the peritoneal surface interposed between the lower
uterine segment and sigmoid colon which demonstrated
slightly hyperintense T2 signal in comparison to muscle with
isointense T1 signal and uniform postcontrast enhancement.
She underwent a second-exploratory laparotomy, tumor
reductive surgery, total abdominal hysterectomy, bilateral
salpingooophorectomy, segmental ileal resection with sideto-side reanastomosis, and repair of the ventral hernia.
Intraoperative findings revealed rectosigmoid nodules as well
as small nodules involving the ileum. Pathology was again
consistent with hemangiopericytoma involving the resected
rectosigmoid nodules, small bowel nodules with microscopic
small bowel serosal residual disease. Histologic examination
revealed uniform spindled to round cells with small amounts
of pale or eosinophilic cytoplasm, indistinct margins, bland
vesicular nuclei, and low mitotic activity. Numerous staghorn
vascular spaces of varying sizes lined by flattened endothelium were also observed. Within the mass were alternating
hypercellular perivascular areas formed by plump cells as well
as hypocellular areas with increased collagen surrounding
individual cells and occasional multinucleated giant cells.
Immunohistochemical stains revealed CD 34 and focal CD
10 positivity. CD31, calretinin, HBME-1 (anti-mesothelioma
antibody), C-kit, keratin, and S-100 all stained negative.
Given findings consistent with recurrent hemangiopericytoma, the plan of care at the time included routine surveillance with no adjuvant chemotherapy/radiation therapy. She
was followed up with imaging of the abdomen/pelvis.
Imaging performed 37 months after the last surgery
showed a 2 cm enhancing solid mass in the left hemipelvis
interposed between the proximal sigmoid serosa and adjacent
small bowel and subjacent to the medial left urinary bladder.
Another adjacent enlarging 1.7 × 1.9 cm enhancing mass
with central necrosis or hypoattenuation was also seen just
above the subjacent bladder and vaginal cuff. The patient
elected to proceed forward with surgical resection and
underwent a third-exploratory laparotomy, extensive lysis of
adhesions, enterolysis, and tumor debulking. Intraoperative
findings included a 3 cm ileal mesenteric mass with additional
tumor nodules (4 cm rectosigmoid mesenteric mass, 3 cm
mesenteric rectosigmoid mass, 3 cm epiploic mass adherent
to mesentery of rectosigmoid, and 3 cm rectosigmoid mesenteric nodule adherent to bladder peritoneum). Pathology
was again consistent with recurrent hemangiopericytoma. No
adjuvant therapy was recommended at the time except close
surveillance and imaging.

3. Discussion
Hemangiopericytomas have a distinct set of clinical,
histopathological, and immunohistochemical features. These
tumors are characterized by a unique staghorn appearance
composed of thin walled vessels surrounded by ovoid and
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short spindle shaped cells [5, 6]. Immunohistochemical
examination will reveal positivity for CD 34, a marker for
platelet endothelial cells, as well as antismooth muscle actin,
type IV collagen, and vimentin, and negativity for S-100
protein and cytokeratin [7]. In our patient, pathological
evaluations of the primary and recurrent tumors were
consistent with hemangiopericytoma.
Hemangiopericytomas in general have been found to
have a favorable prognosis, despite the potential for recurrence and/or metastasis even after surgical management [8,
9]. Enzinger and Smith in 1976 examined 106 patients with
hemangiopericytomas of which follow-up was available on
93 patients [4]. Of the patients who were alive (71), two
had evidence of recurrent disease and four had exhibited
metastatic disease versus thirteen with either recurrent or
metastatic disease in the deceased group (22) [4]. The 10-year
survival was reported as 70% [4]. A more recent study from
MD Anderson published in 1998 found that 32% of primary
hemangiopericytomas had local recurrences on follow-up
with a 5-year actuarial survival of 71% [10]. Another study
by Espat et al. in 2002 reported a 4% local recurrence
rate and a 20% metastatic rate with 2- and 5-year survival
rates of 93% and 86%, respectively [6]. Factors that may
help distinguish between high-grade and low-grade lesions
include cellularity, mitotic activity, and the presence of hemorrhage and necrosis [11]. Malignant hemangiopericytomas
are described as those lesions with large tumor size (>5 cm),
increased mitotic rate (≥4 mitoses per 10 HPF), high degree
of cellularity, presence of immature and pleomorphic tumor
cells, and foci of hemorrhage and necrosis [4]. McMaster et
al. used histologic criteria to classify hemangiopericytomas
as benign, borderline malignant, or malignant [9]. 37.5%
of borderline and 78% of the malignant tumors exhibited
metastasis [9]. Among the tumors with benign histology, the
vascular pattern was rather prominent. Four of the twelve
benign tumors that were examined exhibited slight anaplasia
[9]. No mitotic figures were perceived in nine of these tumors
while only three specimens exhibited 1 mitotic figure per
20 HPF [9]. On the other hand, all the borderline tumors
demonstrated mitotic figures; the average was 1 mitotic figure
per 20 HPF among seven of the sixteen tumors [9]. Tumors
with 1 mitotic figure per 10 HPF and slight cellular anaplasia
or 1 mitotic figure per 20 HPF and moderate cellular anaplasia
were categorized with malignant potential [9]. The histological features of our reported omental hemangiopericytoma
exhibited benign features except for a gross tumor size of
>5 cm which is a feature of malignant behavior. Despite
that, it was best described as a “low malignant potential
tumor.”
Omental hemangiopericytomas represent around 10% of
all primary solid omental tumors [12]. A review of the English
literature revealed 24 cases of omental hemangiopericytoma
inclusive of our patient. The interval to disease recurrence is
relatively delayed with a median duration between primary
diagnosis and the first recurrence estimated at 17 months
(range: 1 month to greater than 7 years) [4]. Other reports
have projected the median time to recurrence at 29 months
[10]. When compared to other soft tissue sarcomas, hemangiopericytomas were noted to have a longer latency period
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prior to the first recurrence [8, 10]. Slupski et al. reported a
recurrence of primary omental hemangiopericytoma occurring 18 years following primary resection [13]. Distant sites
of metastasis include lung, liver, brain, scalp, chest wall,
gastrointestinal tract, bone, orbit, vulva, and lymph nodes
[9, 14]. The first recurrence in our case occurred 52 months
after the primary surgery while the second recurrence ensued
37 months after the second-surgical resection, typical of this
type of lesion.
Surgery with curative intent remains the primary mode
of management of hemangiopericytomas arising from the
omentum [15]. Performance of a complete omentectomy does
not guarantee superior prognosis. Even in those cases in the
literature wherein a total omentectomy was performed, recurrence was often found [12, 16, 17]. Metastatic and recurrent
tumors may benefit from chemotherapy; however, there are
no established chemotherapeutic regimens. Additionally, the
slow progression of these cancers impacts the ability to discern true benefit from chemotherapy in terms of recurrencefree and overall survival [15]. Agents such as Doxorubicin
and Adriamycin used solely or in combination with other
chemotherapeutic drugs have shown good response [16,
18]. Sunitinib, a vascular endothelial growth factor receptor
inhibitor and a platelet-derived growth factor receptor kinase
inhibitor, has also shown favorable clinical benefit [19]. Other
pharmaceutical agents such as pazopanib, a tyrosine-kinase
inhibitor, have exhibited clinical efficacy and the potential
for management of metastatic hemangiopericytomas; however more studies still need to be conducted [20]. Reports
regarding radiation therapy on the other hand have been
inconsistent [16, 21–24]. Our case was managed surgically
with complete resection of the primary tumor and each of
the two successive recurrences. In the interim, patient was
followed up closely both clinically and with serial imaging.
The decision not to give chemotherapy or radiotherapy
in our case despite two local recurrences was based on
multiple considerations including the ability to successfully
resect the lesions, the size, histological appearance of these
recurrences, and the indolent course of this disease. Hemangiopericytomas create a major postoperative challenge for
the provider due to the increased potential for recurrence,
the uncertain timeframe for the disease progression, and
the absence of clear tools to detect recurrences. Some studies have suggested that a yearly PET scan may exemplify
a valid tool for the ascertainment of disease recurrence
[14].

4. Conclusion
Hemangiopericytomas have a high five-year overall survival;
however, given the cellular origin of these tumors, long-term
follow-up is essential as recurrences have been reported even
after extended disease-free intervals. Predictors of recurrence
and metastasis include histological appearance and behavior
of the primary tumor. Surgery remains the chief method of
therapy, with the potential for utilization of chemotherapy
and/or radiation therapy as adjuvants in the more aggressive
malignant cases with an unclear benefit to its use given the
nature of the disease.
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